Compositions and methods for micro-RNA expression profiling of colorectal cancer
The present invention relates compositions and methods for microRNA (miRNA) expression profiling of colorectal cancer. In particular, the invention relates to a diagnostic kit of molecular markers for identifying one or more mammalian target cells exhibiting or having a predisposition to develop colorectal cancer, the kit comprising a plurality of nucleic acid molecules, each nucleic acid molecule encoding a miRNA sequence, wherein one or more of the plurality of nucleic acid molecules are differentially expressed in the target cells and in one or more control cells, and wherein the one or more differentially expressed nucleic acid molecules together represent a nucleic acid expression signature that is indicative for the presence of or the predisposition to develop colorectal cancer. The invention further relates to corresponding methods using such nucleic acid expression signatures for identifying one or more mammalian target cells exhibiting or having a predisposition to develop colorectal cancer as well as for preventing or treating such a condition. Finally, the invention is directed to a pharmaceutical composition for the prevention and/or treatment of colorectal cancer.
1. A diagnostic kit of molecular markers for identifying one or more mammalian target cells exhibiting or having a predisposition to develop colorectal cancer, the kit consisting of a plurality of human target cell-derived nucleic acid molecules encoding the following microRNA sequences: hsa-miR-376a, hsa-miR-424, hsa-miR-378, hsa-miR-375, hsa-miR-139-3p, hsa-miR-18b, hsa-miR-18a, hsa-miR-650, hsa-miR-194*, hsa-miR-194, hsa-miR-29c, hsa-miR-139-5p, hsa-miR-497, hsa-miR-378*, hsa-miR-182, hsa-miR-20b, hsa-miR-17*, hsa-miR-376c, and hsa-miR-20a*, and optionally one or more of hsa-miR-429, hsa-miR-451, hsa-miR-99a, hsa-miR-939, hsa-miR-181c, hsa-miR-513c, hsa-miR-572, hsa-miR-130b, hsa-miR-30e, hsa-miR-455-3p, hsa-miR-192*, hsa-miR-301a, hsa-miR-452, hsa-miR-98, hsa-miR-486-5p, hsa-miR-662, hsa-miR-19b, hsa-miR-30e*, hsa-miR-151-3p, hsa-miR-29c*, hsa-miR-623, hsa-miR-550*, hsa-miR-134, hsa-miR-128, hsa-miR-21*, hsa-miR-638, hsa-miR-335*, hsa-miR-342-5p, hsa-miR-34b*, hsa-miR-145* and hsa-miR-552, wherein:
(i) each of the plurality of human target cell-derived nucleic acid molecules encodes one of the listed microRNA sequences;
(ii) one or more of the human target cell-derived nucleic acid molecules are differentially expressed in the target cells and in one or more control cells; and
(iii) the one or more differentially expressed human target cell-derived nucleic acid molecules together represent a nucleic acid expression signature that is indicative of the presence of or a predisposition to development of colorectal cancer in a human subject.
2. The kit of claim 1 , wherein the colorectal cancer is manifested as an adenocarcinoma.
3. The kit of claim 2 , for the further use of identifying a predisposition to develop colorectal adenoma or a predisposition to develop colorectal carcinoma or a predisposition to develop colorectal adenoma and carcinoma or identifying a progression of an adenoma to an adenocarcinoma or a predisposition for a progression of an adenoma to an adenocarcinoma.
4. The kit of claim 1 , wherein expression of the human target cell-derived nucleic acid molecule encoding hsa-miR-429 is up-regulated and expression of any one or more of the human target cell-derived nucleic acid molecules encoding hsa-miR-376a, hsa-miR-451, and hsa-miR-99a is down-regulated in the one or more target cells as compared to in the one or more control cells.
5. The kit of claim 1 , wherein expression of any of the one or more human target cell-derived nucleic acid molecules encoding hsa-miR-424, hsa-miR-18b, hsa-miR-18a, hsa-miR-181c, hsa-miR-130b, hsa-miR-455-3p, hsa-miR-301 a, hsa-miR-452, hsa-miR-98, hsa-miR-19b, hsa-miR-151-3p, hsa-miR-550*, hsa-miR-128, and hsa-miR-21* is up-regulated and expression of any of the one or more human target cell-derived nucleic acid molecules encoding hsa-miR-378, hsa-miR-375, hsa-miR-139-3p, hsa-miR-650, hsa-miR-194*, hsa-miR-194, hsa-miR-29c, hsa-miR-939, hsa-miR-513c, hsa-miR-572, hsa-miR-30e, hsa-miR-192*, hsa-miR-486-5p, hsa-miR-662, hsa-miR-30e*, hsa-miR-29c*, hsa-miR-623, and hsa-miR-134 is down-regulated in the one or more target cells as compared to in the one or more control cells.
6. The kit of claim 1 , wherein expression of any of the one or more human target cell-derived nucleic acid molecules encoding hsa-miR-182, hsa-miR-20b, hsa-miR-17*, hsa-miR-20a*, hsa-miR-335*, hsa-miR-34b*, and hsa-miR-552 is up-regulated and expression of any of the one or more human target cell-derived nucleic acid molecules encoding hsa-miR-139-5p, hsa-miR-497, hsa-miR-378*, hsa-miR-376c, hsa-miR-638, hsa-miR-342-5p, and hsa-miR-145* is down-regulated in the one or more target cells as compared to in the one or more control cells.